RxDoctor Payments DataLook up a doctor →

Joshua Oaks, MD

Internal Medicine · Bountiful, UTNPI 1205221405

Payments from drug & device makers

$972,534in general payments, 2019–2025

Across 1,133 payments — averaging $858.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$653K
  • Romark Laboratories, LC$190K
  • Novo Nordisk AS$90K
  • Alnylam Pharmaceuticals Inc.$24K
  • Pfizer$1K
  • Amgen$1K
  • plus $13K from 54 others
$100in research payments, 2019–2025

Across 2 payments — averaging $50.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novo Nordisk AS$100

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis56$652,507
Romark Laboratories, LC1$190,000
Novo Nordisk AS30$89,717
Alnylam Pharmaceuticals Inc.3$24,455
Pfizer116$1,458
Amgen(2 entities)96$1,449
AbbVie(2 entities)99$1,417
AstraZeneca69$1,197
Boehringer Ingelheim52$974
Astellas Pharma US Inc44$947
Lilly USA, LLC68$906
Johnson & Johnson47$862
Merck49$672
Amarin Pharma, Inc.57$646
Novo Nordisk44$577
Sanofi-aventis U.S. LLC39$505
GSK25$382
Otsuka America Pharmaceutical, Inc.22$363
Bayer20$320
Daiichi Sankyo Inc.14$241
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)13$228
Dexcom, Inc.12$223
Abbott10$196
Sumitomo Pharma America, Inc.10$157
Boston Scientific9$130
Corcept Therapeutics5$117
Arbor Pharmaceuticals, Inc.8$114
E.r. Squibb & Sons, L.L.C.7$108
Eisai Inc.6$98
Lucid Diagnostics Inc.7$97
Biohaven Pharmaceutical Holding Company Ltd.6$95
Lundbeck LLC4$80
Sanofi Pasteur Inc.5$79
Nestle Healthcare Nutrition Inc.4$74
Idorsia Pharmaceuticals US Inc5$73
Phathom Pharmaceuticals, Inc.7$68
Kowa Pharmaceuticals America, Inc.5$63
Neurocrine Biosciences, Inc.3$60
Amneal Pharmaceuticals LLC4$58
Axsome Therapeutics, Inc.3$57
Mylan Specialty L.p.3$55
Edwards Lifesciences2$49
Actelion Pharmaceuticals US, Inc.3$46
Teva Pharmaceuticals USA, Inc.3$42
Indivior Inc.2$38
Bristol Myers Squibb2$35
Grifols USA, LLC2$34
Ultragenyx Pharmaceutical Inc.2$34
Otsuka Pharmaceutical Development & Commercialization, Inc.2$33
Biohaven Pharmaceuticals, Inc.2$33
Biogen2$32
Seqirus USA Inc2$29
Acadia Pharmaceuticals Inc2$28
Exact Sciences2$27
Organon2$26
Mayne Pharma Commercial LLC2$26
Medtronic2$26
Neurelis, Inc.2$24
Regeneron Healthcare Solutions, Inc.1$21
Xeris Pharmaceuticals, Inc.1$16

How this compares

$972,534 in reported general payments places this provider in the 95th percentile of 496 internal medicine providers in Utah.

See all internal medicine providers in Utah →

Medicare billing

Part B allowed, 2024
$234,592
Medicare patients
362
Services billed
3,447

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Bountiful

See the full list for Utah →

Where these figures come from

Is this you, or does something look wrong? →